What is Bioptix?
Bioptix specializes in providing a comprehensive suite of reagents and assay kits essential for diverse biological research applications, including critical areas like cancer studies and diagnostic testing. Their product portfolio encompasses advanced assay kits, PCR reagents, and specialized cell lines, designed to serve researchers across oncology, immunology, and molecular biology. By delivering high-quality tools, Bioptix aims to empower scientists and healthcare professionals, thereby enhancing research capabilities and diagnostic accuracy. The company serves a broad client base within academic, clinical, and pharmaceutical sectors, with a core mission to advance scientific knowledge and improve patient outcomes.
How much funding has Bioptix raised?
Bioptix has raised a total of $22.7M across 8 funding rounds:
Unspecified
$3.4M
Unspecified
$1.2M
Unspecified
$4.5M
Unspecified
$6.2M
Private Equity
$2.1M
Private Equity
$1.4M
Private Equity
$1.5M
Private Equity
$2.5M
Unspecified (2009): $3.4M with participation from Boulder Ventures
Unspecified (2010): $1.2M, investors not publicly disclosed
Unspecified (2011): $4.5M supported by Boulder Ventures
Unspecified (2013): $6.2M, investors not publicly disclosed
Private Equity (2014): $2.1M, investors not publicly disclosed
Private Equity (2014): $1.4M with participation from Rusnano, Boulder Ventures, and Remeditex
Private Equity (2015): $1.5M, investors not publicly disclosed
Private Equity (2015): $2.5M, investors not publicly disclosed
Key Investors in Bioptix
Boulder Ventures
Boulder Ventures Ltd. is a venture capital firm that specializes in investing in IT and biotech companies located in Colorado and the Mid-Atlantic region. Their focus is on supporting innovative businesses in the technology and biotechnology sectors.
Rusnano
Группа РОСНАНО specializes in the development and optimization of advanced technologies in fields such as microelectronics, biotechnology, and material morphology. The company aims to support various industries by providing innovative solutions and services.
Remeditex
Remeditex seeks to develop opportunities in need of commercial validation, guidance, and capital, aiming to accelerate the commercialization of biomedical research and support a thriving biotechnology industry.
What's next for Bioptix?
The recent major strategic investment signals a pivotal phase for Bioptix, likely indicating a move towards scaling operations, expanding market reach, and potentially accelerating product development pipelines. Given the enterprise-level nature of its funding, Bioptix is poised to make significant advancements in its offerings for biological research. Future strategies may involve deeper penetration into diagnostic markets, further innovation in assay kit technology, and strategic partnerships to broaden its impact on scientific discovery and healthcare solutions. The company's trajectory suggests a focus on solidifying its position as a key provider of essential research tools.
See full Bioptix company page
